Affordable Access

deepdyve-link
Publisher Website

Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021

Authors
  • Seppälä, Elina1, 2
  • Veneti, Lamprini3
  • Starrfelt, Jostein3
  • Danielsen, Anders Skyrud3
  • Bragstad, Karoline4
  • Hungnes, Olav4
  • Taxt, Arne Michael1
  • Watle, Sara Viksmoen1
  • Meijerink, Hinta1
  • 1 Department of infectious disease control and vaccines, Norwegian Institute of Public Health, Oslo, Norway
  • 2 ECDC Fellowship Programme, Field Epidemiology path (EPIET), European Centre for Disease Prevention and Control, (ECDC), Stockholm, Sweden
  • 3 Department of infectious disease control and preparedness, Norwegian Institute of Public Health, Oslo, Norway
  • 4 Department of virology, Norwegian Institute of Public Health, Oslo, Norway
Type
Published Article
Journal
Eurosurveillance
Publisher
European Centre for Disease Control and Prevention (ECDC)
Publication Date
Sep 02, 2021
Volume
26
Issue
35
Identifiers
DOI: 10.2807/1560-7917.ES.2021.26.35.2100793
PMID: 34477054
PMCID: PMC8414959
Source
PubMed Central
Keywords
Disciplines
  • Rapid Communication
License
Unknown

Abstract

Some variants of SARS-CoV-2 are associated with increased transmissibility, increased disease severity or decreased vaccine effectiveness (VE). In this population-based cohort study (n = 4,204,859), the Delta variant was identified in 5,430 (0.13%) individuals, of whom 84 were admitted to hospital. VE against laboratory confirmed infection with the Delta variant was 22.4% among partly vaccinated (95% confidence interval (CI): 17.0−27.4) and 64.6% (95% CI: 60.6−68.2) among fully vaccinated individuals, compared with 54.5% (95% CI: 50.4−58.3) and 84.4% (95%CI: 81.8−86.5) against the Alpha variant.

Report this publication

Statistics

Seen <100 times